Analysts Set Stoke Therapeutics, Inc. (NASDAQ:STOK) Target Price at $21.40

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) have been assigned a consensus recommendation of “Moderate Buy” from the seven brokerages that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $21.40.

A number of research firms recently issued reports on STOK. Wedbush reiterated an “outperform” rating and set a $17.00 target price on shares of Stoke Therapeutics in a research report on Thursday, July 11th. HC Wainwright reiterated a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, September 11th. Finally, Needham & Company LLC restated a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a research note on Thursday, August 8th.

Stoke Therapeutics Price Performance

Stoke Therapeutics stock opened at $12.29 on Friday. The stock’s 50 day moving average is $14.31 and its 200 day moving average is $13.44. Stoke Therapeutics has a one year low of $3.35 and a one year high of $17.58. The firm has a market cap of $640.57 million, a P/E ratio of -5.10 and a beta of 0.96.

Stoke Therapeutics (NASDAQ:STOK) last announced its earnings results on Wednesday, August 7th. The company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.11. The business had revenue of $4.83 million during the quarter, compared to the consensus estimate of $3.33 million. Stoke Therapeutics had a negative net margin of 683.35% and a negative return on equity of 57.89%. Equities analysts anticipate that Stoke Therapeutics will post -2.18 earnings per share for the current fiscal year.

Insider Activity at Stoke Therapeutics

In related news, major shareholder Skorpios Trust sold 1,937,500 shares of the company’s stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $14.05, for a total transaction of $27,221,875.00. Following the sale, the insider now directly owns 8,906,181 shares in the company, valued at approximately $125,131,843.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 11.30% of the stock is currently owned by company insiders.

Institutional Trading of Stoke Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Birchview Capital LP increased its stake in Stoke Therapeutics by 147.1% in the 4th quarter. Birchview Capital LP now owns 210,000 shares of the company’s stock worth $1,105,000 after acquiring an additional 125,000 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Stoke Therapeutics in the first quarter worth approximately $1,224,000. BNP Paribas Financial Markets raised its stake in Stoke Therapeutics by 86.2% in the first quarter. BNP Paribas Financial Markets now owns 14,330 shares of the company’s stock valued at $193,000 after purchasing an additional 6,636 shares in the last quarter. Chase Investment Counsel Corp bought a new stake in Stoke Therapeutics during the first quarter valued at approximately $279,000. Finally, State Board of Administration of Florida Retirement System purchased a new position in Stoke Therapeutics in the 1st quarter worth approximately $141,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.